In this trial, 21 patients with recurrent Taxol- and platinum-refractory ovarian cancer and CEA levels within the reference range, were treated with up to six-fold intraperitoneal administration of MV-CEA, every four weeks, at seven different dose levels ranging from to 103 to 109 TCID50 [156]. This evidence concerns the gene CEACAM5 and ovarian cancer.